Novo Nordisk launches obesity drug Wegovy
U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...
Novo Nordisk's Wegovy launch in China begins in Shanghai at $194 per four-injection pack, significantly cheaper than U.S.
About 400 people marched to the South African headquarters of Novo Nordisk A/S in Johannesburg this week demanding greater ...
Bagsværd, Denmark-based Novo Nordisk is a global healthcare company and a leader in the worldwide diabetes market with a ...
Novo Nordisk (NVO) reportedly plans to phase out production of human insulin pens while it ramps up production of other ...
Investopedia on MSN12d
Novo Nordisk Stock Slips as Sales Grow Less Than ExpectedAfter rising in premarket trading, Novo Nordisk's U.S.-listed shares fell after the market opened Wednesday as its ...
When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion sales in 2023, it shows no signs ...
Novo Nordisk on Wednesday reported third quarter earnings broadly in line with expectations and narrowed its 2024 ...
Novo Nordisk shares were up Wednesday following an earnings report that showed continued sales growth of its obesity drug.
EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback